Akron’s New Line of Closed System Solutions™ & the Production of Next Generation Cell-Based Immunotherapies

Time: 11:30 am
day: Day 1 – Track C – Morning


• The industrialization of cell therapy manufacturing will require a transition to closed system production, with the direct integration of critical ancillary materials
• First to market with a liquid cytokines, Akron now introduces its IL-2 in single-use bags with weldable
tubing, offering minimum activity levels appropriate for manufacturing at any scale
• Akron’s Human AB Serum (converted from Octaplas®) and HSA 25% Closed System Solutions allow for the seamless integration of critical media supplements without compromising sterility